CUPERTINO, Calif., Feb. 27 (HSMN NewsFeed) — DURECT Corporation (Nasdaq: DRRX ) today reported that Endo Pharmaceuticals (Nasdaq: ENDP ) has given notice that it’s returning to us Endo’s rights in the U.S. and Canada to develop and commercialize TRANSD…
Biopharmaceuticals
DURECT, Endo Pharmaceuticals, TRANSDUR, Sufentanil

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT”
Leave a Comment